The prognostic value of pretreatment Glasgow Prognostic Score in patients with esophageal cancer: a meta-analysis
Authors Wang Y, Li P, Li J, Lai Y, Zhou K, Wang X, Che G
Received 29 January 2019
Accepted for publication 22 July 2019
Published 4 September 2019 Volume 2019:11 Pages 8181—8190
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Cristina Weinberg
Peer reviewer comments 2
Editor who approved publication: Dr Rituraj Purohit
Yan Wang*, Pengfei Li*, Jue Li, Yutian Lai, Kun Zhou, Xin Wang, Guowei Che
Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Guowei Che
Department of Thoracic Surgery, West China Hospital, Sichuan University, Guoxuexiang No. 37, Chengdu, People’s Republic of China
Tel +86 281 898 060 1890
Fax +86 288 542 2494
Objectives: To examine the predictive role of Glasgow Prognostic Score (GPS) on long-term survival in esophageal cancer.
Method: Comprehensive searches of electronic databases were performed to identify potential studies that evaluated the prognostic value of pretreatment GPS in esophageal cancer patients. We combined the hazard ratios (HRs) with 95% confidence intervals (CIs) to assess the association of GPS with overall survival (OS), disease-free survival (DFS) and cancer-specific survival (CSS).
Results: A total of 21 studies including 6115 patients were analyzed. Compared with patients with GPS 0, patients with elevated GPS had poorer OS (HR =2.12, 95% CI: 1.83–2.45, P<0.001) and CSS (HR =2.16, 95% CI: 1.56–2.98, P<0.001); but no significant relationship was observed between the elevated GPS and DFS (HR=2.14, 95% CI:1.00–4.61, P=0.051). Subgroup analysis outcomes were similar to overall analyses.
Conclusion: Pretreatment GPS could serve as a valuable factor in predicting the prognosis of patients with esophageal cancer. More well-designed prospective studies are warranted to confirm our findings.
Keywords: esophageal cancer, Glasgow Prognostic Score, survival, meta-analysis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]